Home › Compare › BOVNF vs SCHD
BOVNF yields 60.82% · SCHD yields 3.77%● Live data
📍 BOVNF pulled ahead of the other in Year 1
Combined, BOVNF + SCHD cover 4 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOVNF + SCHD for your $10,000?
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
Full BOVNF Calculator →SCHD tracks the Dow Jones U.S. Dividend 100 Index, focusing on quality companies with consistent dividend histories. With $60B+ AUM, it's the most popular dividend ETF in the US — combining income with quality. Only companies with 10+ consecutive years of dividends qualify. The ETF rebalances annually and has delivered market-beating total returns since inception in 2011.
Full SCHD Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.